4.73
1.63 (52.58%)
| Previous Close | 3.10 |
| Open | 3.05 |
| Volume | 2,743,208 |
| Avg. Volume (3M) | 135,764 |
| Market Cap | 18,177,282 |
| Price / Sales | 91.86 |
| Price / Book | 1.07 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | -13.22 |
| Total Debt/Equity (MRQ) | 28.27% |
| Current Ratio (MRQ) | 0.960 |
| Operating Cash Flow (TTM) | -9.16 M |
| Levered Free Cash Flow (TTM) | -3.67 M |
| Return on Assets (TTM) | -71.24% |
| Return on Equity (TTM) | -268.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Quantum Biopharma Ltd. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 11.41% |
| % Held by Institutions | 23.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tucker Asset Management Llc | 31 Dec 2025 | 1,114 |
| Atlantic Union Bankshares Corp | 31 Dec 2025 | 1,000 |
| Cetera Trust Company, N.A | 31 Dec 2025 | 250 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |